In the dynamic landscape of global life sciences, France has emerged as a frontrunner in fostering innovation and accelerating the integration of digital medical devices (DMDs) through groundbreaking regulatory reforms. The recent approval of the PECAN (Prise en Charge Anticipée) initiative signifies a monumental leap forward, positioning France alongside visionary counterparts in Europe.
The PECAN initiative, approved in 2021, revolves around the rapid exceptional reimbursement of CE-marked DMDs specifically designed for remote medical monitoring or therapeutic purposes (DTx). This groundbreaking scheme is applicable exclusively to prescribed DMDs presumed to be innovative, reflecting France’s commitment to embracing cutting-edge technologies in the healthcare sector. This move places France at a pivotal juncture, drawing comparisons with Germany, a legal trailblazer with its DiGA Verzeichnis, and Spain, currently in the process of formulating regulations addressing DMD reimbursement.
Go deeper with GlobalData
What sets France apart is its strategic framework, empowering DMD operators to initiate operational deployment with exceptional reimbursement while concurrently pursuing the traditional reimbursement application. This application must be submitted before the end of the transitional period, ensuring a seamless transition from exceptional to ordinary reimbursement. In contrast, countries like the UK have implemented a transitional system, exemplified by the EVA system used by NICE, while the Netherlands lacks a specific transitional period reimbursement system for its DMDs.
The latest development in France comes in the form of three pivotal orders, dated October 25, signed by the Ministries of Health and Economy. These orders augment the existing framework, providing clarity and direction to both practitioners and industry stakeholders.
The first order delineates specific information that prescribers must include on prescriptions to facilitate DMD reimbursement. This additional information complements verbal instructions, emphasising the anticipated and exceptional nature of reimbursement. This transparency is crucial for fostering understanding and buy-in from the medical community.
See Also:
The second order establishes the financial compensation structure, defining technical flat-rate tariffs that remunerate operators and retail distributors providing remote medical monitoring DMDs. These monthly, non-cumulative tariffs, assigned per patient, supplement those outlined in a preceding order from May 2023, which set flat-rate amounts for remote medical monitoring activities covered by French health insurance. This comprehensive compensation model aligns incentives for operators, encouraging widespread adoption of DMDs.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe third order marks a significant milestone by enabling the reimbursement of the first DMD for remote medical monitoring. While Germany boasts 55 listed and reimbursed DMDs, this inaugural step in France signifies the beginning of a transformative era for digital healthcare solutions in the country.
Navigating challenges: practitioner and patient adoption of DMDs
However, the efficacy of these regulatory changes ultimately hinges on their practical adoption by practitioners and patients. Despite the monumental strides taken by France, there remains uncertainty surrounding the extent to which healthcare professionals and individuals will leverage these new opportunities. It is incumbent upon decision-makers in global life sciences companies to recognise and capitalise on the potential presented by this regulatory landscape.
For decision-makers in the life sciences industry, this represents an unparalleled opportunity to position their innovative DMDs in a market ripe for growth. The French regulatory environment, with its emphasis on rapid exceptional reimbursement, provides a unique advantage for companies looking to introduce novel digital solutions. The transparency in reimbursement procedures, outlined in the recent orders, facilitates smoother integration into the healthcare system.
Moreover, the financial compensation structure outlined in the second order ensures that operators and distributors are adequately remunerated for their contributions to remote medical monitoring. This incentivises companies to invest in research, development, and deployment of cutting-edge DMDs, fostering a vibrant ecosystem of digital health innovation.
As life sciences companies navigate the complexities of international markets, understanding and leveraging the nuances of each regulatory landscape is paramount. France’s strategic approach not only expedites market entry for DMDs but also establishes a foundation for sustainable growth. Decision-makers should view France as a key player in the evolving landscape of digital healthcare and position their companies to seize the immense potential offered by the PECAN initiative. France’s commitment to innovation was also underscored at the recent AI for Health Summit held in Paris this month.
In conclusion, France’s progressive regulatory framework for digital medical devices signifies a paradigm shift in the global life sciences landscape. Decision-makers in life sciences companies must recognise the strategic advantages presented by France’s approach and capitalise on the unprecedented opportunities for growth and innovation in the burgeoning digital healthcare sector. The recent orders, coupled with the PECAN initiative, position France at the forefront of digital health adoption, making it a strategic focal point for companies aiming to lead the next wave of innovation in the life sciences industry.
